Initial Experience with Combined Interferon-α2b and Carbon Dioxide Laser for the Treatment Of Condylomata Acuminata

Davis, Bradley E.; Noble, Mark J.

doi:10.1016/s0022-5347(17)37326-3

Cited by 31 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reichman et al (58) found that intralesional interferon alfa-2b therapy of condyloma (without prior CO 2 laser treatment) achieved complete regression of a single treated wart in 53% of patients who were treated with 1 million units three times per week for 3 weeks (58). Short-term recurrence rates after CO 2 laser and interferon-␣ are 18-21%-much lower than laser therapy alone (55,56). At 6-months follow-up, 71% of interferon-treated patients were free of disease (59).…”

Section: Adjuvant Therapymentioning

confidence: 98%

“…Flulike symptoms, including fever, chills, fatigue, nausea, vomiting, diarrhea, and headache, are most pronounced during the first few injections and respond to around-the-clock acetaminophen (56). Flulike symptoms, including fever, chills, fatigue, nausea, vomiting, diarrhea, and headache, are most pronounced during the first few injections and respond to around-the-clock acetaminophen (56).…”

Section: Wound Care Cautions and Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of verruca vulgaris and condyloma acuminatum with lasers

Sood¹,

Hruza²

2000

Dermatologic Therapy

View full text Add to dashboard Cite

Section: Adjuvant Therapymentioning

confidence: 98%

Section: Wound Care Cautions and Complicationsmentioning

confidence: 99%

Treatment of verruca vulgaris and condyloma acuminatum with lasers

Sood¹,

Hruza²

2000

Dermatologic Therapy

View full text Add to dashboard Cite

“…Its efficacy in combination with CO 2 laser has been demonstrated by significantly decreased recurrence rates compared to those treated with CO 2 laser alone [84]. Patients treated with intralesional IFN-β 1a 3 times weekly for 3 weeks did not show a significantly better complete response rate than those treated with placebo, although partial response was significantly higher than in the control group [85].…”

Section: Other Topical and Locally Acting Antineoplastic Agentsmentioning

confidence: 99%

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Grossberg

Gaspari

2011

Topical Applications and the Mucosa

View full text Add to dashboard Cite

Topical antineoplastic agents have a well-established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5-fluorouracil (5-FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open-label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5-FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well-defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Toll-like receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

show abstract

“…The administration of topical, intralesional, perilesional, and systemic IFN concurrently or after surgery, CO 2 laser, electrocauterization, or cryotherapy has promising potential for the treatment of anogenital warts. A number of controlled studies have found that adjuvant perilesional IFN and IFN gel given after CO 2 laser ablation leads to a significant reduction in the recurrence rate 63–67 . Further analysis of studies combining systemic IFN with the above ablative therapies reveals the results to be confusing, mixed, and inconsistent.…”

Section: Fda Approved Usesmentioning

confidence: 99%